HC Wainwright Has Negative Outlook of ARTL FY2024 Earnings

Artelo Biosciences, Inc. (NASDAQ:ARTL) – Stock analysts at HC Wainwright decreased their FY2024 earnings estimates for Artelo Biosciences in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst V. Bernardino now forecasts that the company will post earnings of ($2.62) per share for the year, down from their previous estimate of ($2.41). HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Artelo Biosciences’ current full-year earnings is ($2.62) per share. HC Wainwright also issued estimates for Artelo Biosciences’ Q4 2024 earnings at ($0.74) EPS and FY2025 earnings at ($1.61) EPS.

Separately, EF Hutton Acquisition Co. I upgraded Artelo Biosciences to a “strong-buy” rating in a research note on Tuesday, October 1st.

Artelo Biosciences Trading Down 3.7 %

Shares of ARTL stock opened at $1.04 on Monday. The company has a 50 day simple moving average of $1.15 and a two-hundred day simple moving average of $1.27. The stock has a market cap of $3.36 million, a P/E ratio of -0.36 and a beta of 1.35. Artelo Biosciences has a 12 month low of $1.00 and a 12 month high of $1.75.

Artelo Biosciences (NASDAQ:ARTL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.06.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.